Across Europe and the USA, community-acquired pneumonia (CAP) affects 100 per 100,000 adults a year and has a mortality rate of 10û20%. However, where antibiotic therapy has been received within four hours of admission there has been a 15% reduction in mortality.
With clinical guidelines advising against the routine use of antibiotics for respiratory tract infections, BinaxNOW can help to reduce inappropriate antibiotic prescribing and in turn prevent the risk of antibiotic resistance occurring in strains of respiratory infection.
Additionally, the BinaxNOW S. pneumoniae rapid test can also be used for the swift diagnosis of pneumococcal meningitis from cerebrospinal fluid (CSF). The BinaxNOW range of rapid tests for respiratory infections covers influenza A and B, Legionella, RSV, Strep A and S. pneumoniae. With an easy-to use book-shaped test device, Inverness Medical continues to enable early and accurate diagnosis of disease with its BinaxNOW rapid tests.
Inverness Medical www.binax.com